Aptose Biosciences Inc.
APTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.88 | 0.50 | -1.50 |
| FCF Yield | -119.87% | -8.67% | -4.03% | -2.41% |
| EV / EBITDA | 0.00 | -9.69 | -18.06 | -27.03 |
| Quality | ||||
| ROIC | 0.00% | 2,776.03% | -109.11% | -87.48% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.41 | 0.87 | 0.77 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 19.36% | -37.94% | 25.67% | -28.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.16 | 0.84 | 0.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2,685.90 | -4,553.51 | -1,005.85 |